[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2001253282A1 - Compositions and methods related to canine igg and canine il-13 receptors - Google Patents

Compositions and methods related to canine igg and canine il-13 receptors

Info

Publication number
AU2001253282A1
AU2001253282A1 AU2001253282A AU5328201A AU2001253282A1 AU 2001253282 A1 AU2001253282 A1 AU 2001253282A1 AU 2001253282 A AU2001253282 A AU 2001253282A AU 5328201 A AU5328201 A AU 5328201A AU 2001253282 A1 AU2001253282 A1 AU 2001253282A1
Authority
AU
Australia
Prior art keywords
canine
receptors
compositions
methods related
igg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001253282A
Inventor
Catherine A. Mccall
Liang Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heska Corp
Original Assignee
Heska Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heska Corp filed Critical Heska Corp
Publication of AU2001253282A1 publication Critical patent/AU2001253282A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2001253282A 2000-04-07 2001-04-09 Compositions and methods related to canine igg and canine il-13 receptors Abandoned AU2001253282A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19587400P 2000-04-07 2000-04-07
US19565900P 2000-04-07 2000-04-07
US60/195,659 2000-04-07
US60/195,874 2000-04-07
PCT/US2001/011498 WO2001077332A2 (en) 2000-04-07 2001-04-09 Compositions and methods related to canine igg and canine il-13 receptors

Publications (1)

Publication Number Publication Date
AU2001253282A1 true AU2001253282A1 (en) 2001-10-23

Family

ID=26891190

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001253282A Abandoned AU2001253282A1 (en) 2000-04-07 2001-04-09 Compositions and methods related to canine igg and canine il-13 receptors

Country Status (4)

Country Link
US (3) US6703360B2 (en)
EP (1) EP1268794A2 (en)
AU (1) AU2001253282A1 (en)
WO (1) WO2001077332A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272085A1 (en) * 2000-09-06 2005-12-08 Hodge Timothy A Methods for forensic and congenic screening
EP1333850B1 (en) * 2000-10-20 2008-08-20 Genetics Institute, Inc. Use of il-13 inhibitors for the treatment of tumors
US7261890B2 (en) 2001-12-21 2007-08-28 Idexx Laboratories, Inc. Methods for using canine immunoglobulin variable domains and caninized antibodies
EP1664114A1 (en) * 2003-06-11 2006-06-07 Wyeth Method for producing a polypeptide
AR049390A1 (en) * 2004-06-09 2006-07-26 Wyeth Corp ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
WO2007002383A2 (en) * 2005-06-24 2007-01-04 Transnetyx, Inc. Methods for forensic and congenic screening
JP2010527916A (en) * 2007-04-23 2010-08-19 ワイス・エルエルシー Methods and compositions for treating IL-13 related disorders and methods for monitoring the treatment
JP5703562B2 (en) * 2008-07-10 2015-04-22 東レ株式会社 Immune inducer and cancer detection method
AU2009270181B2 (en) 2008-07-10 2014-05-29 Toray Industries, Inc. Pharmaceutical composition for treatment and prevention of cancer
WO2010110838A2 (en) * 2009-03-25 2010-09-30 Vet Therapeutics Inc. Antibody constant domain regions and uses thereof
CA2754408A1 (en) * 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Fusion proteins comprising canine fc portions
US9296785B2 (en) 2009-04-17 2016-03-29 Wake Forest University Health Sciences IL-13 receptor binding peptides
US8652470B2 (en) * 2010-03-04 2014-02-18 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD52
US9616120B2 (en) * 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
EP3333188B1 (en) 2010-08-19 2022-02-09 Zoetis Belgium S.A. Anti-ngf antibodies and their use
GB2505352B (en) * 2011-05-06 2016-01-27 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
GB201114858D0 (en) 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
US9580496B2 (en) * 2011-05-06 2017-02-28 Nexvet Australia Pty Ltd Therapeutic canine immunoglobulins and methods of using same
US9328164B2 (en) 2011-05-06 2016-05-03 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
WO2013184871A1 (en) 2012-06-06 2013-12-12 Zoetis Llc Caninized anti-ngf antibodies and methods thereof
WO2014152361A1 (en) * 2013-03-15 2014-09-25 Wake Forest University Health Sciences Antibodies against human and canine il-13ra2
RU2761663C2 (en) 2013-12-20 2021-12-13 Интервет Интернэшнл Б.В. Antibodies to canine pd-1
EP3183366B1 (en) * 2014-08-18 2022-10-19 Adrastia Biotech Corporation Systems and methods of detecting solid tumor cancer
CN107074952B (en) 2014-09-30 2021-04-09 英特维特国际股份有限公司 PD-L1 antibodies that bind canine PD-L1
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
JP2020517262A (en) * 2017-04-21 2020-06-18 キンドレッド バイオサイエンシズ インコーポレイテッド IL4/IL13 receptor molecules for veterinary use
EP3480212B1 (en) 2017-11-03 2023-09-27 Consejo Superior De Investigaciones Científicas Il13ralpha2 peptide and its uses
CA3084262A1 (en) * 2017-12-06 2019-06-13 The Board Of Trustees Of The Leland Stanford Junior University Engineered proteins to enhance sensitivity of a cell to il-2
EP3765499A1 (en) 2018-03-12 2021-01-20 Zoetis Services LLC Anti-ngf antibodies and methods thereof
MX2024002148A (en) 2021-08-20 2024-03-08 Intervet Int Bv Homodimer fusion proteins for treating atopic dermatitis.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2837240B2 (en) 1990-06-07 1998-12-14 財団法人化学及血清療法研究所 Gene fragment encoding constant region of canine immunoglobulin gamma chain and mouse x dog chimeric antibody
AU640397B2 (en) * 1989-08-25 1993-08-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin
MD1652G2 (en) 1991-03-29 2001-12-31 Sanofi-Synthelabo Protein possessing the cytokin - type activity, recombinant DNA-codifyer for such protein, transformed cells and microorganism, expression vector, process for protein obtaining and remedy containing such a protein
US5449002A (en) * 1992-07-01 1995-09-12 Goldman; Robert J. Capacitive biofeedback sensor with resilient polyurethane dielectric for rehabilitation
US5596072A (en) 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
US5738849A (en) 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US5696234A (en) 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
US5622842A (en) 1994-11-09 1997-04-22 Merck & Co., Inc. DNA encoding canine immunoglobulin A
US5629415A (en) 1994-11-09 1997-05-13 Merck & Co., Inc. DNA encoding canine immunoglobulin E
US6428788B1 (en) 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
US5614191A (en) 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5830453A (en) 1995-05-19 1998-11-03 Emory University Use of IL-13 to induce 15-lipoxygenase
FR2742156A1 (en) 1995-12-06 1997-06-13 Sanofi Sa IL-13 RECEPTOR POLYPEPTIDE
US5935824A (en) * 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
WO1998010638A1 (en) 1996-09-10 1998-03-19 Amrad Operations Pty. Ltd. Therapeutic molecules
US20020137139A1 (en) * 1999-01-12 2002-09-26 Byatt John C Nucleic acid and other molecules associated with lactation and muscle and fat deposition

Also Published As

Publication number Publication date
US6703360B2 (en) 2004-03-09
EP1268794A2 (en) 2003-01-02
US7378275B2 (en) 2008-05-27
US20020165135A1 (en) 2002-11-07
WO2001077332A3 (en) 2002-07-25
US20040142372A1 (en) 2004-07-22
WO2001077332A2 (en) 2001-10-18
US20080287665A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
AU2001253282A1 (en) Compositions and methods related to canine igg and canine il-13 receptors
AU2001255196A1 (en) Compositions and methods for enhancing immunogenicity of antigens
HK1061403A1 (en) ANTIBODIES TO HUMAN IL-1ß
EP1551875A4 (en) Buffered formulations for concentrating antibodies and methods of use thereof
HK1203521A1 (en) Antibodies to nsulin-like growth factor receptor
AU4835001A (en) Antibodies to human cd154
EP1592440A4 (en) Immunoglobulin formulation and method of preparation thereof
AU8390301A (en) Antibodies to human MCP-1
AU2001234437A1 (en) Deicing compositions and methods of use
AU2002320057A1 (en) Herbal composition for improving oral hygiene, and methods of using same
AU2001271502A1 (en) Methods and compositions for isolating biologically active antibodies
AU2002353383A1 (en) Cleaning and desinfecting herbal compositions and their preparation
AU2003266815A1 (en) Immunoglobulin compositions and methods
AU2003261053A1 (en) Fuel additive composition and its preparation
AU7522401A (en) Non-agonistic antibodies to human gp39, compositions containing, and therapeuticuse thereof
AU2003276844A8 (en) Formulations of modified antibodies and methods of making the same
AU2001233086A1 (en) Ceramidase compositions and methods based thereon
AU2001276581A1 (en) Compositions for inducing self-specific anti-ige antibodies and uses thereof
AU2002226059A1 (en) Improved compositions and methods for producing antibodies to low molecular weight analytes
AU2001253481A1 (en) Methods and compositions for eleciting an immune response
EP1572878A4 (en) Compositions and methods for inferring a response to a statin
AU2003254016A1 (en) Methods and compositions relating to chimeric nicotinic receptor subunits
AU2001278204A1 (en) Methods of selecting and cloning animals
AU5000800A (en) Constitutive chimeric receptors, and methods of use thereof
AU2003224761A8 (en) Mcp-1 mutant proteins, antibodies, compositions, methods and uses